Lamivudine's efficacy and safety in preventing mother-to-child transmission of hepatitis B: A meta-analysis.
Adult
Antiviral Agents
/ administration & dosage
Female
Hepatitis B, Chronic
/ transmission
Humans
Infant, Newborn
Infectious Disease Transmission, Vertical
/ prevention & control
Lamivudine
/ administration & dosage
Male
Pregnancy
Pregnancy Complications, Infectious
/ drug therapy
Prenatal Care
/ methods
Treatment Outcome
Journal
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
ISSN: 2148-5607
Titre abrégé: Turk J Gastroenterol
Pays: Turkey
ID NLM: 9515841
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
pubmed:
27
11
2018
medline:
23
4
2019
entrez:
27
11
2018
Statut:
ppublish
Résumé
Mother-to-child transmission (MTCT) is a common transmission mode of hepatitis B virus (HBV). It has been shown that the infection may occur in some infants despite the use of immunoprophylaxis, and many studies have demonstrated the efficacy of antivirals such as lamivudine to reduce such events. A meta-analysis was conducted concerning the efficacy and safety of lamivudine during pregnancy, in the prevention of vertical transmission of HBV infection. Studies were identified by searching various databases up to January 2016 for variations of the following phrase: "lamivudine AND (pregnancy or pregnant) AND (HBV or hepatitis)." Subjects who had received lamivudine were included in the case group, and those who had not were included in the control group. Our search identified a total number of 881 citations, of which 25 studies (with a total number of 2,667 pregnant women) were included in the meta-analysis. The analysis showed a significant difference between the seropositive HBsAg infants from the case and control groups (RR= 16.97, 95% confidence interval 8.36-34.45), which is the most critical factor in determining the MTCT of HBV. No significant difference was reported between the prevalence of side effects in the case and control groups. This meta-analysis strongly suggests the use of lamivudine in the prevention of HBV vertical transmission in carrier pregnant women with the HBV DNA levels greater than 106 copies/mL. And for women with the HBV viral loads lower than 106 copies/mL, we suggest clinicians to examine the use of lamivudine on a case-to-case basis, noting that lamivudine seems to be a safe drug for the mother and the fetus.
Sections du résumé
BACKGROUND/AIMS
Mother-to-child transmission (MTCT) is a common transmission mode of hepatitis B virus (HBV). It has been shown that the infection may occur in some infants despite the use of immunoprophylaxis, and many studies have demonstrated the efficacy of antivirals such as lamivudine to reduce such events.
MATERIALS AND METHODS
A meta-analysis was conducted concerning the efficacy and safety of lamivudine during pregnancy, in the prevention of vertical transmission of HBV infection. Studies were identified by searching various databases up to January 2016 for variations of the following phrase: "lamivudine AND (pregnancy or pregnant) AND (HBV or hepatitis)." Subjects who had received lamivudine were included in the case group, and those who had not were included in the control group.
RESULTS
Our search identified a total number of 881 citations, of which 25 studies (with a total number of 2,667 pregnant women) were included in the meta-analysis. The analysis showed a significant difference between the seropositive HBsAg infants from the case and control groups (RR= 16.97, 95% confidence interval 8.36-34.45), which is the most critical factor in determining the MTCT of HBV. No significant difference was reported between the prevalence of side effects in the case and control groups.
CONCLUSION
This meta-analysis strongly suggests the use of lamivudine in the prevention of HBV vertical transmission in carrier pregnant women with the HBV DNA levels greater than 106 copies/mL. And for women with the HBV viral loads lower than 106 copies/mL, we suggest clinicians to examine the use of lamivudine on a case-to-case basis, noting that lamivudine seems to be a safe drug for the mother and the fetus.
Identifiants
pubmed: 30475212
doi: 10.5152/tjg.2018.18148
pmc: PMC6389296
doi:
Substances chimiques
Antiviral Agents
0
Lamivudine
2T8Q726O95
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
66-74Références
J Viral Hepat. 2003 Jul;10(4):294-7
pubmed: 12823596
World J Gastroenterol. 2003 Jul;9(7):1501-3
pubmed: 12854150
World J Gastroenterol. 2004 Mar 15;10(6):910-2
pubmed: 15040044
BMJ. 2006 Feb 11;332(7537):328-36
pubmed: 16443611
Zhonghua Fu Chan Ke Za Zhi. 2008 May;43(5):329-31
pubmed: 18953863
J Viral Hepat. 2009 Feb;16(2):91-3
pubmed: 19175877
J Viral Hepat. 2009 Feb;16(2):94-103
pubmed: 19175878
Obstet Gynecol. 2010 Jul;116(1):147-59
pubmed: 20567182
World J Gastroenterol. 2010 Oct 28;16(40):5042-6
pubmed: 20976840
J Infect Dev Ctries. 2011 Apr 26;5(4):303-6
pubmed: 21537073
Int J Gynaecol Obstet. 2011 Jul;114(1):33-6
pubmed: 21592475
World J Gastroenterol. 2011 Oct 14;17(38):4321-33
pubmed: 22090789
J Viral Hepat. 2012 Feb;19(2):e18-25
pubmed: 22239517
Eur J Clin Microbiol Infect Dis. 2012 Sep;31(9):2211-8
pubmed: 22314409
Lancet. 2012 May 26;379(9830):2019-21
pubmed: 22549045
World J Gastroenterol. 2012 Dec 7;18(45):6645-50
pubmed: 23236240
Zhonghua Gan Zang Bing Za Zhi. 2012 Dec;20(12):888-91
pubmed: 23522247
J Viral Hepat. 2014 Nov;21(11):809-17
pubmed: 24329944
J Clin Virol. 2014 Sep;61(1):55-60
pubmed: 24994007
Hepatology. 2014 Aug;60(2):468-76
pubmed: 25187919
Pediatr Infect Dis J. 2014 Sep;33(9):897-903
pubmed: 25361021
Eur J Clin Microbiol Infect Dis. 2015 Mar;34(3):619-23
pubmed: 25381607
Infect Dis Obstet Gynecol. 2014;2014:546165
pubmed: 25548510
Arch Public Health. 2014 Nov 10;72(1):39
pubmed: 25810908
J Obstet Gynaecol Res. 2015 Dec;41(12):1870-6
pubmed: 26369498
Hepatology. 2016 Jan;63(1):319-33
pubmed: 26565396
Hepatology. 2016 Jan;63(1):261-83
pubmed: 26566064